A surgical orthotopic xenograft approach with immune response for colorectal cancer research

Abstract

The high morbidity and mortality of colorectal cancer (CRC) is a major challenge in clinical practice. Although a series of alternative research models of CRC have been developed, appropriate orthotopic animal models that reproduce the specific clinical response as well as pathophysiological immune features of CRC are still lacking. In the current study, we constructed a CRC orthotopic xenograft model by implanting the tumor tubes at the colorectum of mice and monitored the model development using bioluminescence imaging. This model successfully recapitulates the clinical chemotherapy efficacy, including reduced total flux, tumor weight, and the expression of Ki67 after treatment of the first-line chemotherapy regime of CRC (FOLFOX: oxaliplatin and 5-fluorouracil/calcium folinate). The model also reproduced the immunosuppressive effect of FOLFOX, indicated by decreased infiltration of macrophages and increased Treg cells in tumor. Additionally, the orthotopic xenograft approach may be applied in immunodeficient NCG/NSG mice for constructing patient-derived xenografts, and being used in clinical precision medicine and drug evaluation. We believe the current model is a successful surgical orthotopic xenograft approach for cancer research and deserves to be popularized, which will provide a convenient and efficient platform for in-depth mechanism exploration of CRC and preclinical drug evaluation.

Keywords

animal model / colorectal cancer / orthotopic tumor model / tumor immunology

References

[1] Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023; 72(2): 338-344.

[2] Neufert C, Heichler C, Brabletz T, et al. Inducible mouse models of colon cancer for the analysis of sporadic and inflammation-driven tumor progression and lymph node metastasis. Nat Protoc. 2021; 16(1): 61-85.

[3] Gurley KE, Moser RD, Kemp CJ. Induction of colon cancer in mice with 1,2-dimethylhydrazine. Cold Spring Harb Protoc. 2015; 2015(9): pdb.prot077453.

[4] Fahrer J, Kaina B. Impact of DNA repair on the dose-response of colorectal cancer formation induced by dietary carcinogens. Food Chem Toxicol. 2017; 106: 583-594.

[5] Reddy BS, Mori H. Effect of dietary wheat bran and dehydrated citrus fiber on 3,2′-dimethyl-4-aminobiphenyl-induced intestinal carcinogenesis in F344 rats. Carcinogenesis. 1981; 2(1): 21-25.

[6] Machado VF, Parra RS, Leite CA, et al. Experimental model of rectal carcinogenesis induced by N-methyl-N-nitrosoguanidine in mice with endoscopic evaluation. Int J Med Sci. 2020; 17(16): 2505-2510.

[7] Ren J, Sui H, Fang F, Li Q, Li B. The application of Apc(min/+) mouse model in colorectal tumor researches. J Cancer Res Clin Oncol. 2019; 145(5): 1111-1122.

[8] Sakamoto K, Lin B, Nunomura K, Izawa T, Nakagawa S. The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors. Sci Rep. 2022; 12(1): 8121.

[9] Sakai E, Nakayama M, Oshima H, et al. Combined mutation of Apc, Kras, and Tgfbr2 effectively drives metastasis of intestinal cancer. Cancer Res. 2018; 78(5): 1334-1346.

[10] Herberg M, Siebert S, Quaas M, et al. Loss of Msh2 and a single-radiation hit induce common, genome-wide, and persistent epigenetic changes in the intestine. Clin Epigenetics. 2019; 11(1): 65.

[11] Choi SH, Huang AY, Letterio JJ, Kim BG. Smad4-deficient T cells promote colitis-associated colon cancer via an IFN-γ-dependent suppression of 15-hydroxyprostaglandin dehydrogenase. Front Immunol. 2022; 13: 932412.

[12] Drost J, van Jaarsveld RH, Ponsioen B, et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature. 2015; 521(7550): 43-47.

[13] Fumagalli A, Drost J, Suijkerbuijk SJ, et al. Genetic dissection of colorectal cancer progression by orthotopic transplantation of engineered cancer organoids. Proc Natl Acad Sci USA. 2017; 114(12): E2357-E2364.

[14] Zhang Y, Zhang L, Zheng S, et al. Fusobacterium nucleatum promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-κB/ICAM1 axis. Gut Microbes. 2022; 14(1): 2038852.

[15] Zhang Y, Davis C, Shah S, et al. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol Carcinog. 2017; 56(1): 272-287.

[16] Fumagalli A, Suijkerbuijk SJE, Begthel H, et al. A surgical orthotopic organoid transplantation approach in mice to visualize and study colorectal cancer progression. Nat Protoc. 2018; 13(2): 235-247.

[17] de Sousa e Melo F, Kurtova AV, Harnoss JM, et al. A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature. 2017; 543(7647): 676-680.

[18] O'Rourke KP, Loizou E, Livshits G, et al. Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nat Biotechnol. 2017; 35(6): 577-582.

[19] Roper J, Tammela T, Cetinbas NM, et al. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat Biotechnol. 2017; 35(6): 569-576.

[20] Fontana CM, Van Doan H. Zebrafish xenograft as a tool for the study of colorectal cancer: a review. Cell Death Dis. 2024; 15(1): 23.

[21] Liu X, Xin Z, Wang K. Patient-derived xenograft model in colorectal cancer basic and translational research. Animal Model Exp Med. 2023; 6(1): 26-40.

[22] Wang W, Li Y, Lin K, Wang X, Tu Y, Zhuo Z. Progress in building clinically relevant patient-derived tumor xenograft models for cancer research. Animal Model Exp Med. 2023; 6(5): 381-398.

[23] Xie J, Lin Y. Patient-derived xenograft models for personalized medicine in colorectal cancer. Clin Exp Med. 2020; 20(2): 167-172.

[24] Jin KT, Du WL, Lan HR, et al. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: a comprehensive review. Cancer Sci. 2021; 112(7): 2592-2606.

[25] Hou XY, Zhang P, Du HZ, et al. Prevotella contributes to individual response of FOLFOX in colon cancer. Clin Transl Med. 2021; 11(9): e512.

[26] Hou X, Du H, Deng Y, et al. Gut microbiota mediated the individualized efficacy of temozolomide via immunomodulation in glioma. J Transl Med. 2023; 21(1): 198.

[27] Hou X, Zhang P, Du H, et al. Akkermansia Muciniphila potentiates the antitumor efficacy of FOLFOX in colon cancer. Front Pharmacol. 2021; 12: 725583.

[28] Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 27(5): 663-671.

[29] Bell HN, Huber AK, Singhal R, et al. Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer. Cell Metab. 2023; 35(1): 134-149.e6.

[30] Feng H, Guo Z, Chen X, et al. Excessive HSP70/TLR2 activation leads to remodeling of the tumor immune microenvironment to resist chemotherapy sensitivity of mFOLFOX in colorectal cancer. Clin Immunol. 2022; 245: 109157.

[31] Guan Y, Kraus SG, Quaney MJ, Daniels MA, Mitchem JB, Teixeiro E. FOLFOX chemotherapy ameliorates CD8 T lymphocyte exhaustion and enhances checkpoint blockade efficacy in colorectal cancer. Front Oncol. 2020; 10: 586.

[32] Aristin Revilla S, Kranenburg O, Coffer PJ. Colorectal cancer-infiltrating regulatory T cells: functional heterogeneity, metabolic adaptation, and therapeutic targeting. Front Immunol. 2022; 13: 903564.

[33] Basak U, Sarkar T, Mukherjee S, et al. Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol. 2023; 14: 1295257.

[34] Feng WQ, Zhang YC, Xu ZQ, et al. IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8 + T-cell tumour infiltration. J Transl Med. 2023; 21(1): 3335.

[35] Sharma BR, Kanneganti TD. Inflammasome signaling in colorectal cancer. Transl Res. 2023; 252: 45-52.

[36] Kanemaru H, Yamane F, Fukushima K, et al. Antitumor effect of Batf2 through IL-12 p40 up-regulation in tumor-associated macrophages. Proc Natl Acad Sci USA. 2017; 114(35): E7331-E7340.

[37] Zhu L, Song H, Zhang L, Meng H. Characterization of IL-17-producing Treg cells in type 2 diabetes patients. Immunol Res. 2019; 67(4-5): 443-449.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.